Using individualized pharmacokinetics of early MTX elimination as an early clearance biomarker – Resonance

Resonance posted on LinkedIn about recent paper by Nicolás Tentoni et al., titled “Early therapeutic drug monitoring of methotrexate and its association with acute kidney injury: A retrospective cohort study” published on Wiley Online Library.

Authors: Nicolás Tentoni, Miriam Hwang, Gabriela Villanueva, Ryan Combs, Jennifer Lowe, Laura B. Ramsey, Zachary L. Taylor, Thais Murciano Carrillo, María Dolores Aumente, Teresa López-Viñau López, Carmelo Rizzari, Scott C. Howard.

“Using individualized pharmacokinetics of early MTX elimination soon after infusion completion as an early clearance biomarker to predict the potential development of AKI may help prevent nephrotoxicity and improve the safety and efficacy of HDMTX.

By identifying patients at risk of AKI sooner, healthcare providers can implement protective strategies like increased hydration, augmented leucovorin rescue, and glucarpidase in the early hours, when they have the potential to make the most difference.”